Immediate Adverse Events Following COVID-19 Vaccination in Australian Pharmacies: A Retrospective Review.

ABSTRACT:

Background

Four COVID-19 vaccines are approved for use in Australia: Pfizer-BioNTech BNT162b2 (Comirnaty), AstraZeneca ChAdOx1 (Vaxzevria), Moderna mRNA-1273 (Spikevax), and Novavax NVX-CoV2373 (Nuvaxovid). We sought to examine the type and management of immediate adverse events following immunisation (I-AEFI) after COVID-19 vaccination.

Methods

Retrospective review of I-AEFI recorded between July 2021 and June 2022 in 314 community pharmacies in Australia.

Results

I-AEFI were recorded in 0.05% (n = 526/977,559) of all COVID-19 vaccinations (highest: AstraZeneca (n = 173/161,857; 0.11%); lowest: Pfizer (n = 50/258,606; 0.02%)). The most common reactions were: (1) syncope, after the first dose of AstraZeneca (n = 105/67,907; 0.15%), Moderna (n = 156/108,339; 0.14%), an

SUBMITTER: Gallo AT 

PROVIDER: S-EPMC9787804 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature